CAS: 96201-88-6; Sodium 6-Fluoro-2-(2'-Fluoro-[1,1'-Biphenyl]-4-yl)-3-Methylquinoline-4-Carboxylate

该化合物是一个化学化合物,其结构复杂,包括一个由各种功能组替代的芯.该化合物具有氟原子双苯双性,有助于其独特的电子特性和潜在的生物活动.氨基酸组的存在,该组已分解成钠,增强了其在水生环境中的溶性,使其适合医药和材料科学的各种应用.氟替代物已知会影响化合物的亲脂性和反应,可能影响其与生物目标的相互作用.此外,该化合物可能因其芳香结构而表现出有趣的光物理特性,这与荧光探针或感应器的发展有关.

结构式图片

相似化合物

96201-22-8 627907-08-8 627907-09-9

合成工艺路线路线简述

    📜布喹那置于sodium Hydroxide体系中,化学反应生成 布列奎钠
    参考文献:抑制二氢乳清酸脱氢酶克服了急性髓系白血病的分化阻断.
    标题:抑制二氢乳清酸脱氢酶克服了急性髓系白血病的分化阻断.
    摘要:虽然急性髓性白血病 (Aml) 包括许多不同的遗传亚型,但一个共同的标志是白血病成髓细胞停滞在未成熟和自我更新的发展阶段.克服分化停滞的疗法代表了一种强大的治疗策略.我们利用观测到,尽管存在遗传异质性,但大多数 Aml 都共享 Hoxa9 的表达,Hoxa9 是一种在骨髓分化过程中通常下调的基因.使用条件 Hoxa9 模型系统,我们进行了高通量表型筛选并定义了克服分化封锁的化合物.目标识别导致意外发现,抑制二氢乳清酸脱氢酶 (Dhodh) 可在人和小鼠 Aml 模型中实现骨髓分化.体内,Dhodh 抑制剂减少了白血病细胞的负担,降低了白血病起始细胞的水平,并提高了存活率.这些数据证明了 Dhodh 作为分化代谢调节剂的作用,并指出其抑制是克服 Aml 中分化阻断的策略.
    DOI:10.1016/j.Cell.2016.08.057

    海关参考信息

    专利信息


    专利号:US-2012177593-A1
    优先权日:2009-07-20
    标 题 :Synthesis of dendrimer conjugates
    发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
    权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

    专利号:WO-2022226312-A1
    优先权日:2021-04-22
    标 题:Combination nucleotide pool depletion for treatment of viral infections and cancers
    发明人:KUMAR VIKRAM; HESSON DAVID; DEMAREST JAMES
    权利人:CLEAR CREEK BIO INC
    摘要:The invention provides methods of treating cancers and viral infections by providing a combination of agents that inhibit both nucleotide synthesis and nucleotide salvage in the cells of a subject to prevent cancer proliferation and viral replication. The invention provides methods of depleting nucleotide pools by using both inhibitors of dihydroorotate dehydrogenase (DHODH), such as brequinar, which block synthesis of pyrimidine-based nucleotides, in combination of one or more nucleotide salvage inhibitors, for example deoxycytidine kinase (dCK) inhibitors, Equilibrative nucleoside transporter (ENT) inhibitors, and Uridine-cytidine kinase (UCK) inhibitors, which inhibit salvage of purine and/or pyrimidine-based nucleotides or nucleosides

    专利号:US-8734846-B2
    优先权日:2008-06-16
    标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
    发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
    权利人:BIND BIOSCIENCES INC
    摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

    专利号:US-2013035307-A1
    优先权日:2010-01-26
    标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
    发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
    权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
    摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

    专利号:US-2008214827-A1
    优先权日:2004-02-03
    标 题:Synthesis of Cyanoimino-Benzoimidazoles
    发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
    权利人:EURO CELTIQUE SA
    摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

    专利号:US-2025289827-A1
    优先权日:2022-12-02
    标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
    发明人:YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
    权利人:C4 THERAPEUTICS INC
    摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Horvat NK, Lesinski GB. Bring on the brequinar: an approach to enforce the differentiation of myeloid-derived suppressor cells. J Clin Invest. 2022 Dec 1;132(23):e165506. doi: 10.1172/JCI165506.
    2: Khairy A, Hammoda HM, Celik I, Zaatout HH, Ibrahim RS. Discovery of potential natural dihydroorotate dehydrogenase inhibitors and their synergism with brequinar via integrated molecular docking, dynamic simulations and in vitro approach. Sci Rep. 2022 Nov 9;12(1):19037. doi: 10.1038/s41598-022-23006-1.
    3: Demarest JF, Kienle M, Boytz R, Ayres M, Kim EJ, Patten JJ, Chung D, Gandhi V, Davey RA, Sykes DB, Shohdy N, Pottage JC Jr, Kumar VS. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Antiviral Res. 2022 Oct;206:105403. doi: 10.1016/j.antiviral.2022.105403. Epub 2022 Aug 28.

    合成参考文献


    参考文献:10.1007/bf00182069
    摘要:Indudhara R, Khauli RB. Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols. World Journal of Urology. 1996 Aug;14(4):206–17. doi: 10.1007/bf00182069.
    参考文献:10.1007/bf00182076
    摘要:Hodge EE. The role of mycophenolate mofetil in clinical renal transplantation. World Journal of Urology. 1996 Aug;14(4):249–55. doi: 10.1007/bf00182076.
    参考文献:10.1186/s13045-019-0749-y
    摘要:Brzezinka K, Nevedomskaya E, Lesche R, Steckel M, Eheim AL, Haegebarth A, Stresemann C. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia. Journal of Hematology & Oncology. 2019 Jun 28;12(1):66. doi: 10.1186/s13045-019-0749-y.
    参考文献:10.1007/bf02088121
    摘要:Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Digestive Diseases and Sciences. 1994 Sep;39(9):1885–92. doi: 10.1007/bf02088121.
    参考文献:10.1007/bf03257162
    摘要:Corrigan CJ. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med. 2002;1(1):47–54. doi: 10.1007/bf03257162.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知